Clinical trial No longer in our active list Interventional Ages 60 and up

Home-based electrical stimulation to help older adults at risk of falling

Official title: Feasibility of Home-based tES for Older Adults at Risk of Falling

Run by Hebrew SeniorLife · NCT04732533 · Data updated 2026-05-14

This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.

This study is testing a home-based electrical stimulation treatment to see if it can help older adults who have fallen improve their mobility and reduce their risk of falling again.

Quick facts

Study typeInterventional
Ages60 Years and up
SexAll
Enrollment72 (estimated)
SponsorHebrew SeniorLife
Academic / other
Locations1 site (Roslindale, Massachusetts)
Trial IDNCT04732533 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include ambulatory adults aged 60 and older who have experienced falls or have concerns about falling, along with a caregiver who can administer the treatment.

Probably not a fit

Patients who do not have a caregiver available to administer the treatment or those with severe cognitive impairments may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project aims to assess the feasibility of a caregiver-administered, home-based transcranial electrical stimulation (tES) intervention designed to improve mobility in older adults who have experienced falls. The study involves a four-phase approach, starting with the development of training materials for participants and their caregivers. In the pilot phase, pairs of participants will test the home-based tES system to evaluate its practicality and effectiveness in enhancing mobility and reducing fall risk. The intervention is particularly focused on older adults with cognitive challenges that affect their balance and mobility.

Why it matters

Potential benefit: If successful, this intervention could significantly reduce the risk of falls among older adults, improving their mobility and overall quality of life.

How similar studies have gone: While the use of tES in clinical settings has shown promise, this home-based approach is relatively novel and has not been extensively tested in similar studies.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Inclusion criteria will be the same for PF/PA pairs in both Phase 1 and Phase 2 of the study. All participant pairs who complete either Phase 1 or 2 will be eligible to complete Phase 3. All participant teams who complete Phase 3 in its entirety will be eligible to complete Phase 4

PF group:

* Aged 60+
* Self-report of one or more falls within the past year, and/or concern of falling in the future, and/or self-report of Parkinson's disease.
* Able to read, write, and communicate in English
* Able to identify an eligible PA to participate with them in the study

PA group:

* At least 21 years of age
* Able to read, write, and communicate in English
* Self-reported computer proficiency and willingness to learn how to use tDCS
* Stated availability during weekdays throughout the study period to administer tDCS to the PF

Exclusion Criteria:

* Exclusion criteria will be the same for PF/PA pairs in both Phase 1 and Phase 2 of the study.

PF group:

* Evidence of cognitive impairment that would likely interfere with one's ability to understand the study protocol, risks/benefits, and testing procedures. This will be defined as self-reported diagnosis of Alzheimer's disease or dementia, a score of ≤19 on the Telephone Interview for Cognitive Status (TICS) at the time of telephone screening, a score of 18 or less on the Montreal Cognitive Assessment (MoCA) during the in-person screen, or an inability to understand study procedures following review of the Informed Consent form.
* Inability to stand or ambulate unassisted for at least 25 feet.
* Contraindications to tDCS, including a reported seizure within the past two years, use of neuro-active drugs, the risk of metal objects in the brain, skull, or head, self-reported presence of specific implanted medical devices (e.g., deep brain stimulator, medication infusion pump, cochlear implant), or the presence of any active, uncontrolled dermatological condition, such as eczema, on the scalp.

PA group:

* Mild cognitive impairment defined by a TICS score ≤34 during the phone screen, a MoCA score ≤24 during the in-person screen, or insufficient understanding of study procedures following review of the Informed Consent form.
* Poor eyesight, severe arthritis in the hands, pain, deformity or other condition that interferes with successful administration of tDCS.

Where it's running

  • Hebrew Rehabilitation Center
    Roslindale, Massachusetts, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.